Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
Sant P. Chawla(Hematology Oncology Associates), George D. Demetri(Dana-Farber Cancer Institute)
Cited by 247
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k